Taishi Nakamura

Associate Professor

Kumamoto University Hospital
Country flagJapan
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Background and Aims Ambient PM2.5 exposure is a known risk factor for acute myocardial infarction (AMI). Myocardial infarction with non-obstructive coronary arteries (MINOCA) represents a distinct subtype of AMI from myocardial infarction with obstructive coronary disease (MI-CAD). Public health measures during the COVID-19 pandemic may have altered exposure patterns, offering a natural experiment. This study investigated changes in the association between short-term exposure to PM2.5 and AMI subtypes following the COVID-19 pandemic. Methods Using data from the nationwide JROAD-DPC database, this study analysed 270 091 first-admission AMI patients, including 23 037 MINOCA, between April 2012 and March 2022. A time-stratified case-crossover design with conditional logistic regression estimated the odds ratio (OR) for each 10-μg/m³ increase in PM2.5 exposure at a 2-day lag. The study period was divided into pre-pandemic and post-pandemic phases using 7 April 2020, as the threshold. Sensitivity analyses used alternative pandemic onset dates. Results Each 10-μg/m³ increase in lag-2 PM2.5 was significantly associated with an increased risk of AMI. Although the ORs for overall AMI and MI-CAD remained largely unchanged between periods, a significant attenuation of the PM2.5-related risk for MINOCA was observed (pre-pandemic OR 1.303, 95% confidence interval [CI] 1.005–1.688; post-pandemic OR 1.230, 95% CI: .973–1.555; P for interaction = 0.017). Sensitivity analyses confirmed these findings. Conclusions Short-term exposure to PM2.5 is associated with increased risk of AMI. The observed reduction in MINOCA risk following the COVID-19 pandemic suggested that public health interventions aimed at reducing air pollution exposure may reduce cardiovascular risks, particularly in specific AMI subtypes.

Year:

2026

BACKGROUND Accurately predicting left ventricular ejection fraction (LVEF) recovery after percutaneous coronary intervention (PCI) in patients with chronic coronary syndrome (CCS) is crucial for clinical decision-making. OBJECTIVE This study aimed to develop and compare multiple machine learning (ML) models to predict LVEF recovery and identify key contributing features. METHODS We retrospectively analyzed 520 patients with CCS from the Clinical Deep Data Accumulation System database. Patients were categorized into 4 binary classification tasks based on baseline LVEF (≥50% or <50%) and degree of recovery: (1) good recovery, defined as an LVEF increase of >10% compared with ≤0%; and (2) normal recovery, defined as an LVEF increase of 0% to 10% compared with ≤0%. For each task, 3 feature selection strategies (all features, least absolute shrinkage and selection operator [LASSO] regression, and recursive feature elimination [RFE]) were combined with 4 ML algorithms (extreme gradient boosting [XGBoost], categorical boosting, light gradient boosting machine, and random forest), resulting in 48 models. Models were evaluated using 10-fold cross-validation and assessed by the area under the curve (AUC), decision curve analysis, and calibration plots. RESULTS The highest AUCs were achieved by RFE combined with XGBoost (AUC=0.93) for preserved LVEF with good recovery, LASSO combined with XGBoost (AUC=0.79) for preserved LVEF with normal recovery, LASSO combined with XGBoost (AUC=0.88) for reduced LVEF with good recovery, and RFE combined with XGBoost (AUC=0.84) for reduced LVEF with normal recovery. Shapley Additive Explanation analysis identified uric acid, platelets, hematocrit, brain natriuretic peptide, glycated hemoglobin, glucose, creatinine, baseline LVEF, left ventricular end-diastolic internal diameter, heart rate, R wave amplitude in V5, and R wave amplitude in V6 as important predictive factors of LVEF recovery. CONCLUSIONS ML models incorporating feature selection strategies demonstrated strong predictive performance for LVEF recovery after PCI. These interpretable models may support clinical decision-making and can improve the management of patients with CCS after PCI. CLINICALTRIAL

Year:

2025

Aims Cardiovascular diseases are a leading cause of death globally, and effective self-management is critical for patient outcomes. Integrating Internet of Things-enabled devices with smartphone applications presents a novel approach to enhancing self-management, yet challenges with digital literacy and device usability persist, especially among the elderly. This study aimed to evaluate the adherence, ease of use, and impact on health awareness of a smartphone-connected remote monitoring system among cardiovascular outpatients in Japan. Methods and results We conducted a single-centre, prospective survey at Kumamoto University Hospital involving 10 cardiovascular outpatients (median age: 72.5 years) including heart failure (n = 2), hypertension (n = 3), post-cardiac surgery (n = 2), and others (n = 3). Participants received Bluetooth-enabled monitoring devices and a smartphone app for automatic data synchronization. Adherence, ease of use, and changes in health awareness were assessed through a structured questionnaire. The study found that 8 of 10 participants adhered to daily monitoring, with an average usage period of 48 days. Nine of 10 required minimal support with device use and 8 of 10 reported increase in health awareness. Seven of 10 indicated they could continue using it long term. The average recommendation score was 8.8/10. The timely detection of asymptomatic paroxysmal atrial fibrillation in one patient highlighted the system's potential clinical benefits. Conclusion This pilot study suggests that a smartphone-connected remote monitoring system may enhance self-management practices and health awareness among cardiovascular outpatients. While the findings are promising, larger studies with longer follow-up periods are needed to confirm these results and evaluate the system's impact on clinical outcomes.

Year:

2024

Aims Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is often accompanied by atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia (AT), which are difficult to control because beta-blockers and antiarrhythmic drugs can worsen heart failure (HF). This study aimed to investigate the outcomes of catheter ablation (CA) for AF/AFL/AT in patients with ATTRwt-CM and propose a treatment strategy for CA. Methods and results A cohort study was conducted on 233 patients diagnosed with ATTRwt-CM, including 54 who underwent CA for AF/AFL/AT. The background of each arrhythmia and the details of the CA and its outcomes were investigated. The recurrence-free rate of AF/AFL/AT overall in ATTRwt-CM patients with multiple CA was 70.1% at 1-year, 57.6% at 2-year, and 44.0% at 5-year follow-up, but CA significantly reduced all-cause mortality [hazard ratio (HR): 0.342, 95% confidence interval (CI): 0.133–0.876, P = 0.025], cardiovascular mortality (HR: 0.378, 95% CI: 0.146–0.981, P = 0.045), and HF hospitalization (HR: 0.488, 95% CI: 0.269–0.889, P = 0.019) compared with those without CA. There was no recurrence of the cavotricuspid isthmus (CTI)–dependent AFL, non-CTI–dependent simple AFL terminated by one linear ablation, and focal AT originating from the atrioventricular (AV) annulus or crista terminalis eventually. Twelve of 13 patients with paroxysmal AF and 27 of 29 patients with persistent AF did not have recurrence as AF. However, all three patients with non-CTI–dependent complex AFL not terminated by a single linear ablation and 10 of 13 cases with focal AT or multiple focal ATs originating beyond the AV annulus or crista terminalis recurred even after multiple CA. Conclusion The outcomes of CA for ATTRwt-CM were acceptable, except for multiple focal AT and complex AFL. Catheter ablation may be aggressively considered as a treatment strategy with the expectation of improving mortality and hospitalization for HF.

Year:

2024

Collaborators (10)

Kazuomi Kario

-

JAPAN
View details

Hideo Fujita

professor

Jichi Medical University Saitama Medical Center

JAPAN
View details

Shinsuke Hanatani

Assistant Professor

Kumamoto University

JAPAN
View details

Yoshihiro Miyamoto

Director General

National Cerebral and Cardiovascular Center

JAPAN
View details

Tetsuya Matoba

Associate Professor

Kyushu University Hospital

JAPAN
View details

Masaharu Nakayama

Professor

Tohoku University

JAPAN
View details

Kenichi Tsujita

Professor of Medicine

Kumamoto University

JAPAN
View details

Satoshi Yasuda

Professor and chairmam

Tohoku University graduate school of medicine

JAPAN
View details

Yuichiro Arima

Kumamoto University

JAPAN
View details

Jun Takahashi

Associate Professor

Tohoku University Hospital

JAPAN
View details